Xlife Sciences AG: Breakthrough in Drug Development
Xlife Sciences AG (XLS DE): Breakthrough in Drug Development First available holistic medical drug to treat Covid-19 and flu viruses As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses. The patented active substance ProcCluster(R) reduces the viral load by 90% and acts against infection-related inflammatory processes without developing a resistance. It is already used on humans. The active pharmaceutical ingredient ProcCluster(R) developed by inflamed pharma GmbH is membrane permeable and is based on the active ingredient procaine. It acts both locally as well as systemically and is characterized by a wide range of applications in inflammatory diseases. ProcCluster(R) is already used for various prescription drugs for humans. In various case studies, renowned medical doctors have now been able to successfully demonstrate the effectiveness in the treatment of Covid-19 and Long-Covid patients. In studies with various cell lines, especially lung cells, the active ingredient was able to reduce the viral load by 90% in an early phase and effectively inhibit inflammation in a later phase. These effects can be transferred to other RNA viruses. Oliver R. Baumann, CEO of Xlife Sciences AG, comments: "ProcCluster(R) has enormous market potential because, in contrast to other active ingredients, both the inflammatory processes and the viral load in the body are significantly reduced. This means that it can be used at different points in time during the course of the Covid-19 disease". It is of inestimable value that this active ingredient is already produced by inflamed pharma GmbH in high quality at low cost. "Another key advantage compared to vaccines and antibodies is that ProcCluster(R) does not lead to resistance development and can also be used against virus mutants", continues Baumann. In addition, ProcCluster(R) has a stimulating effect on the microcirculation, which is particularly important for Long-Covid patients. So far, no negative side effects have been observed either. According to the management of Xlife, they are already in various discussions with possible industrial partners in order to have ProcCluster(R) industrially manufactured. The aim is for the active ingredient to be licensed out as quickly as possible. About Xlife Sciences AG Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Language: | English |
Company: | Xlife Sciences AG Klausstrasse 19 8008 Zürich Switzerland |
Phone: | 0041 44 385 84 60 |
E-mail: | |
Internet: | |
ISIN: | CH0461929603 |
WKN: | A2PK6Z |
Listed: | Regulated Unofficial Market in Frankfurt, Munich |
| EQS News ID: | 1206317 |
| End of Announcement | DGAP News Service |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005992/en/
Contact information
For media inquiries: Dennis Lennartz, Head Investor Relations, Xlife Sciences AG, Tel. +41 44 385 84 60, dennis.lennartz@xlifesciences.ch
For scientific inquiries: Dr. Frank Plöger, Chief Scientific Officer, Xlife Sciences AG, Tel. +41 44 385 84 62, frank.ploeger@xlifesciences.ch
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinsted Wealth Selects Objectway for Enhanced and Fully Integrated Client and Investment Management Platform to Drive Growth18.4.2024 15:28:00 CEST | Press release
Objectway, global Top 100 FinTech provider of as-a-service software and services to banks, wealth and asset managers, has partnered with Kinsted Wealth, a Calgary (CAN) based independent wealth manager serving private individuals and institutional investors. Objectway will help Kinsted Wealth manage their business in a fully integrated and centralised manner, ultimately accelerating the growth of its discretionary business and external advisor network. This new client partnership follows the recent addition of leading digital wealth solutions provider Nest Wealth to Objectway, building on the momentum of the Group’s active expansion and operational capability in Canada. Objectway's digital front-end will deliver improved client experience for Kinsted Wealth by providing investors with omnichannel interaction, client engagement and front-office productivity, supported by an online portal and mobile apps for investors. This solution will enable Kinsted Wealth to improve client experience
dataplor Announces Series A Funding Led by Spark Capital to Expand Global Location Data Intelligence18.4.2024 15:00:00 CEST | Press release
dataplor, the leading provider of global location intelligence, today announced a $10.6 million Series A funding round led by Spark Capital. This round, which included participation from Quest Venture Partners, Acronym Venture Capital, Circadian Ventures, Two Lanterns Venture Partners and APA Venture Partners, will further accelerate dataplor’s ongoing expansion, building the most accurate, comprehensive and dynamically updated database of global Point of Interest (POI) data on the market. Today, dataplor offers data coverage across more than 200 countries and territories, encompassing over 300 million locations and over 15,000 brands. Companies in industries including technology, mapping, search, third party logistics, consumer packaged goods (CPG), telecom, investing, real estate and finance rely on dataplor’s global, accurate coverage to power strategic decisions and investments. With this latest funding, dataplor is positioned to expand its worldwide coverage and continue building
Rimini Street Honored with Two Prestigious Stevie® 2024 Awards in the Category of Customer Service18.4.2024 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, has been named a multiple award-winning honoree in the 18th annual Stevie Awards for Sales & Customer Service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418492652/en/ Rimini Street Honored with Two Prestigious Stevie® 2024 Awards in the Category of Customer Service (Photo: Business Wire) A standout amongst the 2,300 nominations received from across the world, Rimini Street received two awards in two different customer service categories: Silver Stevie for Front-Line Customer Service Team of the Year in the Technology Industries category, awarded to the Global Technology Service Delivery team. This esteemed recognition highlights the team's unwavering commitment to excellence in customer service an
Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations18.4.2024 15:00:00 CEST | Press release
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced that Denis Johnson has joined the company as its new Chief Operating Officer (COO). Denis joins Kindeva to lead global operations for all Kindeva’s state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418293964/en/ Denis Johnson joins Kindeva Drug Delivery as Chief Operating Officer, leading Kindeva’s state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K. (Photo: Business Wire) As COO, he will be dedicated to global operations, but notably facilitating the expansion and opening of Kindeva’s new aseptic injectable fill-finish site in Bridgeton, Missouri, opening this year, as well as the company’s focus on bringing green propellants to commercial combination product manufacturing fo
Long Tale Games Relaunches Life is Feudal: MMO on Steam With a Significant Event, the Balance Restoration Campaign18.4.2024 14:00:00 CEST | Press release
Long Tale Games (LTG) announces the Steam relaunch of Life is Feudal: MMO. To show appreciation to the game's community, the publisher is launching a special event aimed at the game's original players, the Balance Restoration Campaign. Players who have made any purchases during the previous Life is Feudal: MMO round will receive special LiF Coins that can be exchanged for a subscription to the game. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418169927/en/ (Graphic: Business Wire) Since the relaunch in June 2023, Life is Feudal: MMO has transitioned to a subscription-based model, removing all pay-to-win features. This shift ensures a level playing field for all players, fostering fairness as success in the game now fully depends on the player's skill and effort, creating a more engaging environment. Until now, the game has only been distributed through the publisher's (LTG.com) own personal gaming platform. However, wi